Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: the BMT CTN-0903/AMC-080 Trial

Richard F. Ambinder, Juan Wu, B. Logan, Christine M. Durand, Ryan Shields, Uday R. Popat, Richard F. Little, Deborah K. McMahon, Joshua Cyktor, John W. Mellors, Ernesto Ayala, Lawrence D. Kaplan, Ariela Noy, Richard J. Jones, Alan Howard, Stephen J. Forman, D. Porter, Carlos Arce-Lara, Paul Shaughnessy, Lisa SproatShahrukh K. Hashmi, Adam M. Mendizabal, Mary M. Horowitz, Willis H. Navarro, Joseph C. Alvarnas

Research output: Contribution to journalArticle

Abstract

We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Hematologic Neoplasms
HIV
Graft vs Host Disease
Transplants
Unrelated Donors
Chimerism
Mortality
Adult Respiratory Distress Syndrome
Liver Failure
Multicenter Studies
Lymphoma
Leukemia
Acquired Immunodeficiency Syndrome
Bone Marrow
Clinical Trials
Viruses
Safety
Survival
DNA
Incidence

Keywords

  • Allogeneic hematopoietic transplantation
  • Bone marrow
  • HIV

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies : the BMT CTN-0903/AMC-080 Trial. / Ambinder, Richard F.; Wu, Juan; Logan, B.; Durand, Christine M.; Shields, Ryan; Popat, Uday R.; Little, Richard F.; McMahon, Deborah K.; Cyktor, Joshua; Mellors, John W.; Ayala, Ernesto; Kaplan, Lawrence D.; Noy, Ariela; Jones, Richard J.; Howard, Alan; Forman, Stephen J.; Porter, D.; Arce-Lara, Carlos; Shaughnessy, Paul; Sproat, Lisa; Hashmi, Shahrukh K.; Mendizabal, Adam M.; Horowitz, Mary M.; Navarro, Willis H.; Alvarnas, Joseph C.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Ambinder, RF, Wu, J, Logan, B, Durand, CM, Shields, R, Popat, UR, Little, RF, McMahon, DK, Cyktor, J, Mellors, JW, Ayala, E, Kaplan, LD, Noy, A, Jones, RJ, Howard, A, Forman, SJ, Porter, D, Arce-Lara, C, Shaughnessy, P, Sproat, L, Hashmi, SK, Mendizabal, AM, Horowitz, MM, Navarro, WH & Alvarnas, JC 2019, 'Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: the BMT CTN-0903/AMC-080 Trial', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.06.033
Ambinder, Richard F. ; Wu, Juan ; Logan, B. ; Durand, Christine M. ; Shields, Ryan ; Popat, Uday R. ; Little, Richard F. ; McMahon, Deborah K. ; Cyktor, Joshua ; Mellors, John W. ; Ayala, Ernesto ; Kaplan, Lawrence D. ; Noy, Ariela ; Jones, Richard J. ; Howard, Alan ; Forman, Stephen J. ; Porter, D. ; Arce-Lara, Carlos ; Shaughnessy, Paul ; Sproat, Lisa ; Hashmi, Shahrukh K. ; Mendizabal, Adam M. ; Horowitz, Mary M. ; Navarro, Willis H. ; Alvarnas, Joseph C. / Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies : the BMT CTN-0903/AMC-080 Trial. In: Biology of Blood and Marrow Transplantation. 2019.
@article{737feddf4abe4f28b32bff7c80ef0a3e,
title = "Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: the BMT CTN-0903/AMC-080 Trial",
abstract = "We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41{\%}. At 1 year, overall survival was 59{\%}; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).",
keywords = "Allogeneic hematopoietic transplantation, Bone marrow, HIV",
author = "Ambinder, {Richard F.} and Juan Wu and B. Logan and Durand, {Christine M.} and Ryan Shields and Popat, {Uday R.} and Little, {Richard F.} and McMahon, {Deborah K.} and Joshua Cyktor and Mellors, {John W.} and Ernesto Ayala and Kaplan, {Lawrence D.} and Ariela Noy and Jones, {Richard J.} and Alan Howard and Forman, {Stephen J.} and D. Porter and Carlos Arce-Lara and Paul Shaughnessy and Lisa Sproat and Hashmi, {Shahrukh K.} and Mendizabal, {Adam M.} and Horowitz, {Mary M.} and Navarro, {Willis H.} and Alvarnas, {Joseph C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.06.033",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies

T2 - the BMT CTN-0903/AMC-080 Trial

AU - Ambinder, Richard F.

AU - Wu, Juan

AU - Logan, B.

AU - Durand, Christine M.

AU - Shields, Ryan

AU - Popat, Uday R.

AU - Little, Richard F.

AU - McMahon, Deborah K.

AU - Cyktor, Joshua

AU - Mellors, John W.

AU - Ayala, Ernesto

AU - Kaplan, Lawrence D.

AU - Noy, Ariela

AU - Jones, Richard J.

AU - Howard, Alan

AU - Forman, Stephen J.

AU - Porter, D.

AU - Arce-Lara, Carlos

AU - Shaughnessy, Paul

AU - Sproat, Lisa

AU - Hashmi, Shahrukh K.

AU - Mendizabal, Adam M.

AU - Horowitz, Mary M.

AU - Navarro, Willis H.

AU - Alvarnas, Joseph C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).

AB - We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).

KW - Allogeneic hematopoietic transplantation

KW - Bone marrow

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=85069900077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069900077&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.06.033

DO - 10.1016/j.bbmt.2019.06.033

M3 - Article

C2 - 31279752

AN - SCOPUS:85069900077

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -